DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Glioblastoma Multiforme Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Glioblastoma Multiforme market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Glioblastoma Multiforme: An Overview
According to the American Brain Tumor Association, Glioblastomas (also called GBM) are malignant Grade IV tumors, where a large portion of tumor cells reproduce and divide at any given time. The tumor is predominantly made up of abnormal astrocytic cells, which also contain a mixture of different cell types (including blood vessels) and areas of dead cells (necrosis). Glioblastomas are infiltrative and invade into nearby regions of the brain. They can also sometimes spread to the opposite side of the brain through connection fibers (corpus callosum).
The mainstay of treatment for GBM is surgery, radiation, and chemotherapy. The primary objective of surgery is to remove as much of the tumor as possible without injuring the surrounding normal brain tissue needed for normal neurological function (such as motor skills, the ability to speak and walk, etc.).
Glioblastoma Multiforme Market Key Facts
-
The total incident population of Glioblastoma Multiforme in the seven major markets was found to be 28,800+ in 2017, which is expected to increase by 2032.
-
According to the Cancer Research Institute, GBM is the most lethal form of brain cancer. There are approximately 16,000 new cases in the U.S. each, year and 10,000 people die annually from the disease.
-
According to DelveInsight’s analysis, severe cases of Glioblastoma Multiforme are more prominent in comparison to mild and moderate cases.
-
In Japan, the incident population of Glioblastoma Multiforme was recorded to be 2,532 in 2017.
-
Among the European 5 countries, the United Kingdom had the highest incident population of Glioblastoma Multiforme, followed by France and Italy. On the other hand, Spain had the lowest incident population.
Glioblastoma Multiforme Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Glioblastoma Multiforme market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Glioblastoma Multiforme market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Glioblastoma Multiforme Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme market or expected to get launched during the study period. The analysis covers Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glioblastoma Multiforme Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market
Glioblastoma Multiforme Therapeutics Analysis
Patients with Glioblastoma Multiforme continue to experience a tremendous burden of treatment, low survival rates, etc. Surgery proves to be a mainstay treatment for Glioblastoma multiforme (GBM). There is a need for developing novel targeted therapies that shall fuel the Glioblastoma multiforme (GBM) market.
Several key companies are actively working in the therapeutics market to fulfill the unmet needs.
Some of the key companies in the Glioblastoma multiforme (GBM) Market include:
-
Tocagen
-
Apogenix
-
Bristol-Myers Squibb
-
Ono Pharmaceuticals
-
Johnpro Biotech
-
AbbVie
-
VBL Therapeutics
-
DelMar Pharmaceuticals
-
Celgene
-
Green Cross Cell Corporation
And many others.
Glioblastoma multiforme (GBM) therapies covered in the report include:
-
Immuncell-LC
-
TTAC-000
-
Nivolumab
-
Ipilimumab
-
Asunercept
-
Marizomib
-
Siroquine (JP001)
-
Toca 511 and Toca FC
-
Dianhydrogalactitol (VAL-083)
-
Ofranergene obadenovec (VB-111)
-
Depatuxizumab mafodotin (ABT-414)
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Glioblastoma Multiforme Competitive Intelligence Analysis
4. Glioblastoma Multiforme Market Overview at a Glance
5. Glioblastoma Multiforme Disease Background and Overview
6. Glioblastoma Multiforme Patient Journey
7. Glioblastoma Multiforme Epidemiology and Patient Population
8. Glioblastoma Multiforme Treatment Algorithm, Current Treatment, and Medical Practices
9. Glioblastoma Multiforme Unmet Needs
10. Key Endpoints of Glioblastoma Multiforme Treatment
11. Glioblastoma Multiforme Marketed Products
12. Glioblastoma Multiforme Emerging Therapies
13. Glioblastoma Multiforme Seven Major Market Analysis
14. Attribute Analysis
15. Glioblastoma Multiforme Market Outlook (7 major markets)
16. Glioblastoma Multiforme Access and Reimbursement Overview
17. KOL Views on the Glioblastoma Multiforme Market.
18. Glioblastoma Multiforme Market Drivers
19. Glioblastoma Multiforme Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Ophthalmic Femtosecond Laser Market
“Ophthalmic Femtosecond Laser Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for the Ophthalmic Femtosecond Laser. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Ophthalmic Femtosecond Laser market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/